Home
SPRY
SPRY News

Latest ARS Pharmaceuticals Inc. (SPRY) News on January 19, 2025

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Investor's Business Daily

5 days ago

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

5 days ago

Exploring Three High Growth Tech Stocks In The United States

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

GlobeNewswire

5 days ago

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

TipRanks

11 days ago

ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

ARS Pharma seeks approval for epinephrine spray in Canada and UK

Medical Device Network

12 days ago

ARS Pharma seeks approval for epinephrine spray in Canada and UK

MT Newswires

12 days ago

ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

GlobeNewswire

12 days ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Top US Growth Companies With Insider Ownership In January 2025

Simply Wall St.

16 days ago

Top US Growth Companies With Insider Ownership In January 2025

Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green

Simply Wall St.

25 days ago

Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

GlobeNewswire

a month ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a month ago

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

a month ago

ARS Pharmaceuticals Insider Sold Shares Worth $1,768,093, According to a Recent SEC Filing

MT Newswires

a month ago

ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

GlobeNewswire

a month ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

MT Newswires

a month ago

ARS Pharmaceuticals Insider Sold Shares Worth $2,041,200, According to a Recent SEC Filing

MT Newswires

a month ago

ARS Pharmaceuticals Insider Sold Shares Worth $2,688,751, According to a Recent SEC Filing

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

GlobeNewswire

a month ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

US Growth Stocks With High Insider Ownership For November 2024

Simply Wall St.

2 months ago

US Growth Stocks With High Insider Ownership For November 2024

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

Simply Wall St.

2 months ago

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

MT Newswires

2 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing

GuruFocus.com

2 months ago

ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

Zacks

2 months ago

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

MT Newswires

2 months ago

ARS Pharmaceuticals' Q3 Net Loss Widens

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

2 months ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

TipRanks

2 months ago

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray

Investor's Business Daily

2 months ago

ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray

ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

Pharmaceutical Technology

2 months ago

ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

MT Newswires

2 months ago

ARS Pharmaceuticals Licenses Neffy Nasal Spray to ALK-Abello for Europe, Canada

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

Benzinga

2 months ago

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

GlobeNewswire

2 months ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet

Zacks

2 months ago

Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

GlobeNewswire

2 months ago

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

MT Newswires

3 months ago

VR Resources Confirms Gold in Porphyry Intrusion Cutting Nickel Sulfide Mineralization at Silverback Project in Ontario

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

GlobeNewswire

3 months ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Simply Wall St.

3 months ago

Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade

Zacks

3 months ago

Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade

Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?

Pharmaceutical Technology

4 months ago

Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?

MT Newswires

4 months ago

ARS Pharmaceuticals Launches Neffy Nasal Spray in US

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

GlobeNewswire

4 months ago

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals (SPRY): A Bull Case Theory

Insider Monkey

4 months ago

ARS Pharmaceuticals (SPRY): A Bull Case Theory

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

GlobeNewswire

4 months ago

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

MT Newswires

4 months ago

ARS Pharmaceuticals Submits Supplemental NDA for Needle-Free Neffy Dose for Children

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

GlobeNewswire

4 months ago

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

Insider Returns Down To US$660k As ARS Pharmaceuticals' Stock Dips 12%

Simply Wall St.

4 months ago

Insider Returns Down To US$660k As ARS Pharmaceuticals' Stock Dips 12%

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why

Zacks

4 months ago

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

GlobeNewswire

4 months ago

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

MT Newswires

5 months ago

ARS Pharmaceuticals Says EC Approves EURneffy for Emergency Treatment of Allergic Reactions

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

GlobeNewswire

5 months ago

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

MT Newswires

5 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $11,497,963, According to a Recent SEC Filing

Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned

Benzinga

5 months ago

Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned

MT Newswires

5 months ago

ARS Pharmaceuticals Insider Sold Shares Worth $1,502,587, According to a Recent SEC Filing

ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares

GuruFocus.com

5 months ago

ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares

ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst

Benzinga

5 months ago

ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst

Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)

GuruFocus.com

5 months ago

Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

Pharmaceutical Technology

5 months ago

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

MT Newswires

5 months ago

ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions

FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment

Benzinga

5 months ago

FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

GlobeNewswire

5 months ago

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

GlobeNewswire

5 months ago

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates

Zacks

5 months ago

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates

ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results

GlobeNewswire

5 months ago

ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results

ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks

6 months ago

ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

US Growth Companies With Insider Ownership As High As 31%

Simply Wall St.

6 months ago

US Growth Companies With Insider Ownership As High As 31%

MT Newswires

7 months ago

ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion

GlobeNewswire

7 months ago

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

US Growth Companies With High Insider Ownership To Watch

Simply Wall St.

7 months ago

US Growth Companies With High Insider Ownership To Watch

Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),

Simply Wall St.

7 months ago

Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),

Top US Growth Companies With High Insider Ownership To Watch In May 2024

Simply Wall St.

8 months ago

Top US Growth Companies With High Insider Ownership To Watch In May 2024

GuruFocus.com

8 months ago

ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...

ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

Simply Wall St.

8 months ago

ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

GlobeNewswire

8 months ago

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

GlobeNewswire

9 months ago

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Barrons.com

9 months ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

GlobeNewswire

9 months ago

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Simply Wall St.

10 months ago

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know

Zacks

10 months ago

ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know

Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why

Zacks

10 months ago

Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why

GuruFocus.com

10 months ago

ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results

GlobeNewswire

10 months ago

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

10 months ago

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

GlobeNewswire

10 months ago

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

GlobeNewswire

a year ago

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

GlobeNewswire

a year ago

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

Simply Wall St.

a year ago

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

GlobeNewswire

a year ago

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

GlobeNewswire

a year ago

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

Thomson Reuters StreetEvents

a year ago

Q4 2023 Pitney Bowes Inc Earnings Call

KKR Real Estate Finance Trust Inc. Tax Treatment of 2023 Dividends

Business Wire

a year ago

KKR Real Estate Finance Trust Inc. Tax Treatment of 2023 Dividends

Unum (UNM) Q4 Earnings Miss Estimates

Zacks

a year ago

Unum (UNM) Q4 Earnings Miss Estimates

Business Wire

a year ago

Hope Bancorp Declares Quarterly Cash Dividend of $0.14 Per Share

Strength Seen in GigaCloud Technology Inc. (GCT): Can Its 10.0% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in GigaCloud Technology Inc. (GCT): Can Its 10.0% Jump Turn into More Strength?

Provident Financial Services Inc Reports Mixed Results Amid Economic Challenges

GuruFocus.com

a year ago

Provident Financial Services Inc Reports Mixed Results Amid Economic Challenges

Here is What to Know Beyond Why Energy Fuels Inc (UUUU) is a Trending Stock

Zacks

a year ago

Here is What to Know Beyond Why Energy Fuels Inc (UUUU) is a Trending Stock

GlobeNewswire

a year ago

Magnite to Announce Fourth Quarter 2023 Financial Results on February 28, 2024

Core Laboratories (CLB) Reports Next Week: What You Should Expect

Zacks

a year ago

Core Laboratories (CLB) Reports Next Week: What You Should Expect

Carlyle Secured Lending, Inc. Schedules Fourth Quarter and Full Year 2023 Financial Results and Investor Conference Call

GlobeNewswire

a year ago

Carlyle Secured Lending, Inc. Schedules Fourth Quarter and Full Year 2023 Financial Results and Investor Conference Call

Beverages and Alcohol Stocks Q3 Recap: Benchmarking PepsiCo (NASDAQ:PEP)

StockStory

a year ago

Beverages and Alcohol Stocks Q3 Recap: Benchmarking PepsiCo (NASDAQ:PEP)

Title Resources Group Welcomes New Executive

PR Newswire

a year ago

Title Resources Group Welcomes New Executive

18 Most Profitable Value Stocks Now

Insider Monkey

a year ago

18 Most Profitable Value Stocks Now

Kura Sushi Must Live Up to High Hopes After Wowing Wall Street

Bloomberg

a year ago

Kura Sushi Must Live Up to High Hopes After Wowing Wall Street

Share on Social Networks: